X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (14) 14
index medicus (10) 10
female (9) 9
humans (9) 9
middle aged (9) 9
aged (8) 8
cancer (7) 7
male (7) 7
adult (6) 6
aged, 80 and over (6) 6
chemotherapy (6) 6
article (5) 5
disease-free survival (5) 5
immunotherapy (5) 5
nivolumab (5) 5
safety (5) 5
survival (5) 5
treatment outcome (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer therapies (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
lung cancer (4) 4
lung cancer, non-small cell (4) 4
research (4) 4
therapy (4) 4
antibodies, monoclonal - administration & dosage (3) 3
antibody (3) 3
apoptosis (3) 3
blockade (3) 3
care and treatment (3) 3
clinical trials (3) 3
lymphocyte count (3) 3
lymphopenia - chemically induced (3) 3
metastasis (3) 3
oncology, experimental (3) 3
pancreatic neoplasms - complications (3) 3
patients (3) 3
pd-l1 (3) 3
pd-l1 protein (3) 3
pembrolizumab (3) 3
safety and security measures (3) 3
tumors (3) 3
abridged index medicus (2) 2
anti-pd-l1 antibody (2) 2
antibodies, monoclonal - adverse effects (2) 2
appetite (2) 2
atezolizumab (2) 2
bladder-cancer (2) 2
breast-cancer (2) 2
carcinoma, non-small-cell lung - complications (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
carcinoma, non-small-cell lung - radiotherapy (2) 2
cell death (2) 2
cell lung-cancer (2) 2
chemoradiotherapy - adverse effects (2) 2
cohort studies (2) 2
disease (2) 2
docetaxel (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
durvalumab (2) 2
fatigue (2) 2
gene expression (2) 2
glioma - complications (2) 2
glioma - drug therapy (2) 2
glioma - radiotherapy (2) 2
head (2) 2
health aspects (2) 2
immune checkpoint inhibitor (2) 2
immunity (2) 2
immunohistochemistry (2) 2
infusions, intravenous (2) 2
ipilimumab (2) 2
ligands (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - mortality (2) 2
lung neoplasms - pathology (2) 2
lymphocytes (2) 2
lymphopenia (2) 2
lymphopenia - pathology (2) 2
medicine, general & internal (2) 2
metastases (2) 2
monoclonal antibodies (2) 2
neoplasm staging (2) 2
non-small cell lung carcinoma (2) 2
open-label (2) 2
original reports (2) 2
ovarian cancer (2) 2
pancreatic cancer (2) 2
pancreatic neoplasms - drug therapy (2) 2
pancreatic neoplasms - radiotherapy (2) 2
pd-1 protein (2) 2
pd-l1 expression (2) 2
phase-iii trial (2) 2
poster presentation (2) 2
radiation-therapy (2) 2
radiotherapy (2) 2
randomized-trial (2) 2
respiratory system (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 299 - 308
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 32, pp. 3223 - 3230
PurposeTumors may evade immunosurveillance through upregulation of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly... 
ONCOLOGY | IDO | INDOLEAMINE 2,3-DIOXYGENASE | COMBINED NIVOLUMAB | INCB024360 | OVARIAN-CANCER | INHIBITORS | COMBINATION | EXPRESSION | IPILIMUMAB | ORIGINAL REPORTS
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 10/2015, Volume 13, Issue 10, pp. 1225 - 1231
Background: The immune system plays an important role in cancer surveillance and therapy. Chemoradiation can cause severe treatmentrelated lymphopenia (TRL)... 
BREAST-CANCER | CELL-LUNG-CANCER | IMMUNE CELLS | METAANALYSIS | THERAPY | ONCOLOGY | INFILTRATING LYMPHOCYTES | ADENOCARCINOMA | T-LYMPHOCYTES | BLOOD | TEMOZOLOMIDE
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 10/2019, Volume 37, Issue 28, pp. 2518 - 2518
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)-expressing nonsmall-cell lung... 
ONCOLOGY | THERAPY | IMMUNOHISTOCHEMISTRY | RAPID COMMUNICATION
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2018, Volume 101, pp. 201 - 209
Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we... 
Non-small-cell lung cancer | PD-L1 | Immune checkpoint inhibitor | Atezolizumab | MULTICENTER | ANTIBODY | OPEN-LABEL | DOCETAXEL | MPDL3280A | TRIAL | ONCOLOGY | LIGAND | NIVOLUMAB | BLOCKADE | Safety and security measures | Metastasis | Research | Lung cancer, Non-small cell | Oncology, Experimental | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. TPS3099 - TPS3099
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2019, Volume 37, Issue 18_suppl, pp. LBA9015 - LBA9015
LBA9015 Background: Pembrolizumab (pembro) monotherapy has demonstrated durable antitumor activity in advanced PD-L1–expressing NSCLC. We present 5-y OS for... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. 6010 - 6010
Journal Article